U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06810960) titled 'A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease' on Jan. 31.
Brief Summary: The primary purpose of this study is to evaluate safety of lecanemab in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in participants treated with lecanemab.
Study Start Date: Jan. 31
Study Type: OBSERVATIONAL
Condition:
Alzheimer's Disease
Intervention:
OTHER: No Intervention
This is a non-intervent...